• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Int J Biol Macromol . The spike glycoproteins of SARS-CoV-2: A review of how mutations of spike glycoproteins have driven the emergence of variants

tetano

Editor, Senior Moderator
Int J Biol Macromol


. 2022 Mar 14;S0141-8130(22)00528-1.
doi: 10.1016/j.ijbiomac.2022.03.058. Online ahead of print.
The spike glycoproteins of SARS-CoV-2: A review of how mutations of spike glycoproteins have driven the emergence of variants with high transmissibility and immune escape


Pedro F N Souza[SUP] 1 [/SUP], Felipe P Mesquita[SUP] 2 [/SUP], Jackson L Amaral[SUP] 3 [/SUP], Patrícia G C Landim[SUP] 3 [/SUP], Karollyny R P Lima[SUP] 3 [/SUP], Marília B Costa[SUP] 2 [/SUP], Izabelle R Farias[SUP] 2 [/SUP], Mônica O Belém[SUP] 4 [/SUP], Yago O Pinto[SUP] 5 [/SUP], Heline H T Moreira[SUP] 5 [/SUP], Ilana C L Magalhaes[SUP] 6 [/SUP], Débora S C M Castelo-Branco[SUP] 7 [/SUP], Raquel C Montenegro[SUP] 3 [/SUP], Claudia R de Andrade[SUP] 4 [/SUP]



Affiliations

Abstract

Late in 2019, SARS-CoV-2 (severe acute respiratory syndrome coronavirus-2) emerged, causing an unknown type of pneumonia today called coronaviruses disease 2019 (COVID-19). COVID-19 is still an ongoing global outbreak that has claimed and threatened many lives worldwide. Along with the fastest vaccine developed in history to fight SARS-CoV-2 came a critical problem, SARS-CoV-2. These new variants are a result of the accumulation of mutations in the sequence and structure of spike (S) glycoprotein, which is by far the most critical protein for SARS-CoV-2 to recognize cells and escape the immune system, in addition to playing a role in SARS-CoV-2 infection, pathogenicity, transmission, and evolution. In this review, we discuss mutation of S protein and how these mutations have led to new variants that are usually more transmissible and can thus mitigate the immunity produced by vaccination. Here, analysis of S protein sequences and structures from variants point out the mutations among them, how they emerge, and the behavior of S protein from each variant. This review brings details in an understandable way about how the variants of SARS-CoV-2 are a result of mutations in S protein, making them more transmissible and even more aggressive than their relatives.

Keywords: Coronaviruses; Mutations; RBD; SARS-CoV-2; Spike proteins.
 
Back
Top Bottom